This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
El estudio post EMPA-KIDNEY, evaluó los efectos de la empagliflozina en pacientes con enfermedad renal crónica. Los hallazgos mostraron que este tratamiento no solo proporcionó beneficios cardiorrenales significativos durante la fase activa del estudio, sino que también mantuvo estos efectos positivos por hasta 12 meses después de la interrupción del tratamiento.
Revisa el resumen visual realizado por Oscar Durón y únete a la conversación en nuestro próximo #NephJC
Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.
Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney
7 ways the EMPA-KIDNEY trial will impact clinical care in CKD
— Daniel Schwartz (@drdschwartzmd) November 27, 2022
A Thread 🧵
Sources @NEJM @NephJC @DiabetesCanada @AmDiabetesAssn @goKDIGO @ESC_Journals @hswapnil @kidney_boy
